On Mar. 17, 2021, the WHO reported that the AstraZeneca COVID-19 vaccine (including Covishield) continued to have a positive benefit-risk profile, with tremendous potential to prevent infections and reduce deaths across the world. To-date, more than 20 million doses of the AstraZeneca vaccine had been administered in Europe and more than 27 million doses of the Covishield vaccine (AstraZeneca vaccine by Serum Institute of India) had been administered in India.

The available data did not suggest any overall increase in clotting conditions such as deep venous thrombosis or pulmonary embolism following administration of COVID-19 vaccines.